The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 21, 2025

Filed:

Apr. 15, 2022
Applicant:

Abelzeta Inc., Rockville, MD (US);

Inventors:

Yihong Yao, Rockville, MD (US);

Yanfeng Li, Hong Kong, CN;

Yutian Wei, Hong Kong, CN;

Shigui Zhu, Rockville, MD (US);

Xin Yao, Rockville, MD (US);

Jiaqi Huang, Rockville, MD (US);

Assignee:

AbelZeta Inc., Rockville, MD (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/47 (2006.01); A61K 35/17 (2025.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
C07K 14/70596 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); A61K 40/4221 (2025.01); A61P 35/00 (2018.01); C12N 5/0636 (2013.01); A61K 2239/29 (2023.05);
Abstract

The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases.


Find Patent Forward Citations

Loading…